Back to top
more

Align Technology (ALGN)

(Delayed Data from NSDQ)

$304.82 USD

304.82
501,730

-4.20 (-1.36%)

Updated Apr 29, 2024 04:00 PM ET

After-Market: $304.61 -0.21 (-0.07%) 7:52 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 252)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Align Technology, based in California, manufactures and markets a system of clear aligner therapy, intra-oral scanners and CAD/CAM (computer-aided design and computer-aided manufacturing) digital services used in dentistry, orthodontics, and dental records storage. The clear aligner system corrects malocclusion using nearly invisible and removable appliances that gently move the tooth to a desired final position.

Reasons to Add Stryker (SYK) Stock to Your Portfolio Now

by Zacks Equity Research

Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio. However, pricing pressure weighs on the stock.

Veeva (VEEV) Rises on Robust Earnings: More Room to Grow?

by Zacks Equity Research

Veeva (VEEV) reports better-than-expected earnings and revenues for the second quarter. The raised earnings outlook for fiscal 2024 reflects optimism. Will the uptrend in shares continue?

Cooper Companies (COO) Q3 Earnings In Line, '23 Outlook Raised

by Zacks Equity Research

Cooper Companies' (COO) third-quarter fiscal 2023 revenues reflect a solid segmental performance with improved adjusted earnings amid rising expenses.

Patterson Companies (PDCO) Q1 Earnings In Line, Sales Hurt by FX

by Zacks Equity Research

Patterson Companies' (PDCO) first-quarter fiscal 2024 results reflect robust improvement in Dental Equipment sales, value-added services and Animal Health segment.

Is Align Technology (ALGN) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Align Technology (ALGN) and Brainsway Ltd. Sponsored ADR (BWAY) have performed compared to their sector so far this year.

Align Technology (ALGN) Down 9% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Align Technology (ALGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Earnings Estimates Rising for Align Technology (ALGN): Will It Gain?

by Zacks Equity Research

Align Technology (ALGN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Align Technology (ALGN) Just Reclaimed the 50-Day Moving Average

by Zacks Equity Research

When a stock breaks out above the 50-Day simple moving average, good things could be on the horizon. How should investors react?

Here's How Much a $1000 Investment in Align Technology Made 10 Years Ago Would Be Worth Today

by Zacks Equity Research

Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

Align (ALGN) Rides on Growing Invisalign Sales, New Alliances

by Zacks Equity Research

Align Technology (ALGN) is expanding its sales and marketing by reaching new countries and regions.

Here's Why You Should Invest in Align Technology (ALGN) Now

by Zacks Equity Research

Investors are optimistic about Align Technology (ALGN), led by Invisalign portfolio expansion and raised guidance.

Quest Diagnostics (DGX) Base Volume Aids Amid Low COVID Tests

by Zacks Equity Research

Quest Diagnostics (DGX) continues to witness growth momentum in the cardiometabolic, endocrinology, infectious disease and carrier and prenatal genetic screening services.

Thermo Fisher (TMO) Business Hurt by Low COVID Sales, FX Woe

by Zacks Equity Research

Thermo Fisher (TMO) is witnessing headwinds in the government and academic end markets.

Bruker (BRKR) Set to Acquire PhenomeX in an All-Cash Deal

by Zacks Equity Research

Bruker (BRKR) initiates its entry into since-cell biology research solutions with the acquisition of PhenomeX.

Here's Why You Should Invest in IDEXX (IDXX) Stock Right Now

by Zacks Equity Research

Investors continue to be optimistic about IDEXX (IDXX) due to the CAG business and the company's execution of its growth strategy.

Cardinal Health (CAH) Beats on Q4 Earnings, Ups '24 EPS View

by Zacks Equity Research

Cardinal Health's (CAH) fiscal fourth-quarter results benefit from the Pharmaceutical segment's solid performance.

Ethan Feller headshot

Prescribing Profits: 3 Stocks to Ride the Healthcare Relative Strength

by Ethan Feller

Over the last month, Healthcare has been the second strongest sector in the market

Align Technology (ALGN) Reports Q2 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

Although the revenue and EPS for Align Technology (ALGN) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

by Zacks Equity Research

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Is ADMA Biologics (ADMA) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Adma Biologics (ADMA) and Align Technology (ALGN) have performed compared to their sector so far this year.

Stock Market News for Jul 27, 2023

by Zacks Equity Research

U.S. stocks ended mixed on Wednesday, with the S&P 500 and the Nasdaq ending slightly lower, as major indexes made a failed attempt to bounce back after the Fed hiked interest rates yet again.

Align Technology (ALGN) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

Align Technology (ALGN) delivered earnings and revenue surprises of 9.90% and 1.65%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

MedTech Stocks' Q2 Earnings Due on Jul 26: DGX, TMO and More

by Urmimala Biswas

MedTech companies' second-quarter results are likely to reflect a year-over-year decline. Let's see how DGX, TMO, EW and ALGN fare this time.

West Pharmaceutical Services (WST) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

West Pharmaceutical (WST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Align Technology (ALGN) to Post Q2 Earnings: What's in Store?

by Zacks Equity Research

Align Technology's (ALGN) second-quarter 2023 results are likely to highlight sustained stability across its Clear Aligner business.